Research on Avacta Group (AVCT) from Trinity Delta
Trinity Delta view: Avacta is now funded through to the early data from the first patients on therapeutic doses of AVA6103 in the Phase I/II FOCUS study; these should provide the first clinical insights on efficacy, kinetics and toxicity. Confirmation of the expected targeted tumour localisation and a reduction in systemic toxicity would be an essential validation step; not simply demonstrating that AVA6103 proposed mechanism is working but de-risking the wider next gen pre|CISION platform. We believe such data should also act as the natural catalysts to drive meaningful commercial partnerships. In the interim, AVA6207, the lead dual payload programme, is close to candidate selection and targeting an IND around end-2027/early 2028. Our Avacta valuation and forecasts are currently suspended; for context, our last published valuation was £525m, or 111p/share (105p fully diluted).
View Full ResearchDisclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
